Ponatinib plus blinatumomab may help “a meaningful subset of patients” forego transplant for Ph-positive acute lymphoblastic leukemia.
|Videos|June 6, 2017
Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
Author(s)Jorge E. Cortes, MD
This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.
Advertisement
In this video, Jorge E. Cortes, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.
Cortes presented the results of the study (
Advertisement
Related to this article
The FDA has assigned a Prescription Drug User Fee Act date of March 31, 2027, for tabelecleucel in this indication.
An expert panel discusses the case for de-escalating antibiotic therapy for pediatric patients who undergo hematopoietic cell transplantation.
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
Advertisement
Advertisement
Trending on CancerNetwork
1
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
2
Reading a Changed Eye Examination and Impact on Therapy
3
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
4
Personalizing Treatment Selection in Platinum-Resistant Ovarian Cancer
5